Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration

References

• Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila). 2017;6(6):493–494.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, for ANCHOR Study Group; et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM; for MARINA Study Group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. 2018;12:2483–2491. doi:10.2147/OPTH.S185052
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Maguire MG, Martin DF, Ying GS, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. 5-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Yu Y, VanderBeek BL. Association of visit adherence and visual acuity in patients with neovascular age-related macular degeneration: secondary analysis of the comparison of age-related macular degeneration treatment trial. JAMA Ophthalmol. 2020;138(3):237–242. doi:10.1001/jamaophthalmol.2019.4577
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193–201. doi:10.1016/j.ophtha.2013.08.011
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Eter N, Fauser S, et al. Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland: behandlungsrealität von Ranibizumab bei nAMD in Deutschland. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany]. Ophthalmologe. 2015;112(3):246–254. German.
   Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100(12):1623–1628. doi:10.1136/bjophthalmol-2015-308166
   PubMed Web of Science ®Google Scholar
• Horner F, Lip PL, Clark H, Chavan R, Sarmad A, Mushtaq B. Real-world visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: an 8-year observational cohort (AMD8). Clin Ophthalmol. 2019;13:2461–2467. doi:10.2147/OPTH.S218378
   Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; for SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi:10.1016/j.ophtha.2013.03.046
   PubMed Web of Science ®Google Scholar
• Gillies M, Arnold J, Bhandari S, et al. Ten-year treatment outcomes of neovascular age-related macular degeneration from two regions. Am J Ophthalmol. 2020;210:116–124. doi:10.1016/j.ajo.2019.10.007
   PubMed Web of Science ®Google Scholar
• Jacob J, Brié H, Leys A, et al. Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. Int J Ophthalmol. 2017;10(1):81–90.
   Web of Science ®Google Scholar
• Yalamanchili SP, Maatouk CM, Enwere DU, et al. The short-term effect of a single lapse in anti-vascular endothelial growth factor treatment for diabetic macular edema within routine clinical practice. Am J Ophthalmol. 2020;219:215–221. doi:10.1016/j.ajo.2020.06.040
   PubMed Web of Science ®Google Scholar
• Chong Teo KY, Saxena N, Gan A, et al. Detrimental effect of delayed re-treatment of active disease on outcomes in neovascular age-related macular degeneration: the RAMPS study. Ophthalmol Retina. 2020;4(9):871–880. doi:10.1016/j.oret.2020.03.017
   PubMedGoogle Scholar
• Hutton-Smith LA, Gaffney EA, Byrne HM, Caruso A, Maini PK, Mazer NA. Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic/pharmacodynamic model. Mol Pharm. 2018;15(7):2770–2784. doi:10.1021/acs.molpharmaceut.8b00280
   Web of Science ®Google Scholar
• DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120(9):721–729. doi:10.7326/0003-4819-120-9-199405010-00001
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Adherence to Long-Term Therapy: Evidence for Action. Geneva: WHO; 2003.
   Google Scholar
• Okada M, Mitchell P, Finger RP, et al. Non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128(2):234–247. doi:10.1016/j.ophtha.2020.07.060
   PubMed Web of Science ®Google Scholar
• Ehlken C, Ziemssen F, Eter N, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258(10):2077–2090. doi:10.1007/s00417-020-04798-2
   PubMed Web of Science ®Google Scholar
• Deutsche Ophthalmologische Gesellschaft (DOG); Retinologische Gesellschaft e.V. (RG); Berufsverband der Augenärzte Deutschlands e.V. (BVA). Therapie bei der neovaskulären altersabhängigen Makuladegenertion: Stand Feburar 2020 [Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration: status February 2020]. Ophthalmologe. 2021;118(Suppl1):31–39. German. doi:10.1007/s00347-020-01188-1
   Google Scholar
• Ehlken C, Helms M, Boehringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13–20. doi:10.2147/OPTH.S151611
   PubMed Web of Science ®Google Scholar
• Müller S, Junker S, Wilke T, et al. Questionnaire for the assessment of adherence barriers of intravitreal therapy: the ABQ-IVT. Int J Retina Vitreous. 2021;7(1):43. doi:10.1186/s40942-021-00311-x
   Google Scholar
• Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–354. doi:10.1111/j.1751-7176.2008.07572.x
   PubMed Web of Science ®Google Scholar
• Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–142. doi:10.1007/s00417-008-0926-0
   PubMed Web of Science ®Google Scholar
• Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2:CD000011.
   Google Scholar
• Sackett DL, Haynes RB, Gibson ES, Taylor DW, Roberts RS, Johnson AL. Patient compliance with antihypertensive regimens. Patient Couns Health Educ. 1978;1(1):18–21. doi:10.1016/S0738-3991(78)80033-0
   Google Scholar
• Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122(7):1308–1316. doi:10.1016/j.ophtha.2015.03.026
   PubMed Web of Science ®Google Scholar
• McClelland JF, Bodle L, Little JA. Investigation of medication adherence and reasons for poor adherence in patients on long-term glaucoma treatment regimes. Patient Prefer Adherence. 2019;13:431–439. doi:10.2147/PPA.S176412
   PubMed Web of Science ®Google Scholar
• Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118(12):2398–2402. doi:10.1016/j.ophtha.2011.05.013
   PubMed Web of Science ®Google Scholar
• Okada M, Wong TY, Mitchell P, et al. Defining nonadherence and nonpersistence to anti–vascular endothelial growth factor therapies in neovascular age-related macular degeneration. JAMA Ophthalmol. 2021;139(7):769–776. doi:10.1001/jamaophthalmol.2021.1660
   Web of Science ®Google Scholar
• Vennedey V, Hower KI, Hillen H, Ansmann L, Kuntz L, Stock S; For the Cologne Research and Development Network (CoRe-Net). Patients’ perspectives of facilitators and barriers to patient-centred care: insights from qualitative patient interviews. BMJ Open. 2020;10(5):e033449. doi:10.1136/bmjopen-2019-033449
   PubMed Web of Science ®Google Scholar
• Subhi Y, Sørensen TL. Neovascular age-related macular degeneration in the very old (≥90 years): epidemiology, adherence to treatment, and comparison of efficacy. J Ophthalmol. 2017;2017:7194927. doi:10.1155/2017/7194927
   PubMed Web of Science ®Google Scholar
• Schroeder M, Westborg I, Adrian ML. Twelve percent of 6142 eyes treated for neovascular age‐related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR). Acta Ophthalmol. 2020;98(3):274–278. doi:10.1111/aos.14239
   Web of Science ®Google Scholar
• Polat O, Inan S, Özcan S, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration. Turk J Ophthalmol. 2017;47(4):205–210. doi:10.4274/tjo.28003
   PubMedGoogle Scholar
• Oishi A, Mandai M, Nishida A, Hata M, Matsuki T, Kurimoto Y. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol. 2011;21(6):777–782. doi:10.5301/EJO.2011.7430
   PubMed Web of Science ®Google Scholar
• Karampelas M, Pefkianaki M, Rees A, et al. Missed hospital appointments of patients receiving ranibizumab therapy for neovascular age-related macular degeneration. Ophthalmol Ther. 2015;4(1):43–49. doi:10.1007/s40123-015-0031-5
   Google Scholar
• Varano M, Eter N, Winyard S, et al. Current barriers to treatment for wet age- related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clin Ophthalmol. 2015;9:2243–2250. doi:10.2147/OPTH.S92548
   Google Scholar
• Study Investigators IVAN, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–1411. doi:10.1016/j.ophtha.2012.04.015
   PubMed Web of Science ®Google Scholar
• Ehlken C, Wilke T, Bauer-Steinhusen U, Agostini HT, Hasanbasic Z, Müller S. Treatment of neovascular age-related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday practice: identification of health care constraints in Germany-the PONS Study. Retina. 2018;38(6):1134–1144. doi:10.1097/IAE.0000000000001681
   Web of Science ®Google Scholar
• Boulanger-Scemama E, Querques G, About F, et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38(7):620–627. doi:10.1016/j.jfo.2014.11.015
   PubMed Web of Science ®Google Scholar
• Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127–140. doi:10.1080/13548506.2016.1274040
   PubMed Web of Science ®Google Scholar
• McGrath LA, Lee LR. Characteristics of patients who drop out from ranibizumab therapy. Asia Pac J Ophthalmol (Phila). 2013;2(5):295–299. doi:10.1097/APO.0b013e31829dc65a
   Google Scholar
• Heimes B, Gunnemann F, Ziegler M, et al. Compliance of age related macular degeneration patients undergoing anti-VEGF therapy: analysis and suggestions for improvement. Ophthalmologe. 2016;113(11):925–932. doi:10.1007/s00347-016-0275-z
   PubMed Web of Science ®Google Scholar
• Chang A, Stokes J, Priestman L, Holmes C, Said P. Impact of a patient support program on patient beliefs about neovascular age-related macular degeneration and persistence to anti-vascular endothelial growth factor therapy. Patient Prefer Adherence. 2021;15:511–521. doi:10.2147/PPA.S293941
   Web of Science ®Google Scholar
• Chiam M, Kunselman AR, Chen MC. Characteristics associated with new patient appointment no-shows at an academic ophthalmology department in the United States. Am J Ophthalmol. 2021;229:210–219. doi:10.1016/j.ajo.2021.02.020
   PubMed Web of Science ®Google Scholar
• Westborg I, Rosso A. Risk factors for discontinuation of treatment for neovascular age-related macular degeneration. Ophthalmic Epidemiol. 2018;25(2):176–182. doi:10.1080/09286586.2017.1397701
   PubMed Web of Science ®Google Scholar
• McClard CK, Wang R, Windham V, et al. Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. BMJ Open Ophthalmol. 2021;6(1):e000669. doi:10.1136/bmjophth-2020-000669
   Web of Science ®Google Scholar
• Abu-Yaghi NE, Abed AM, Khlaifat DF, et al. Factors affecting compliance to anti-vascular endothelial growth factor treatment of diabetic macular edema in a cohort of Jordanian patients. Clin Ophthalmol. 2020;14:921–929. doi:10.2147/OPTH.S248661
   Web of Science ®Google Scholar
• Fajnkuchen F, Delyfer MN, Conrath J, Baillif S, Mrejen S, Srour M. Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections. Acta Diabetol. 2020;57(9):1081–1091. doi:10.1007/s00592-020-01513-9
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Spital G, et al.; Ocean Study Group. Use of imaging modalities in real life: impact on visual acuity outcomes of ranibizumab treatment for neovascular age-related macular degeneration in Germany. J Ophthalmol. 2020;2020:8024258. doi:10.1155/2020/8024258
   Web of Science ®Google Scholar